Eli Lilly's Zepbound Outperforms Novo Nordisk's Wegovy in Obesity Drug Head-to-Head Clinical Trials

Eli Lilly's Zepbound has demonstrated superior performance in head-to-head clinical trials against Novo Nordisk's Wegovy, marking a significant milestone in the competitive weight loss drug market[1]. In the SURMOUNT-5 trial, Zepbound users experienced an average weight loss of 20.2% over 72 weeks, compared to 13.7% for those on Wegovy, translating to a weight reduction of approximately 50 pounds versus 33 pounds, respectively[2]. Notably, 32% of Zepbound users achieved a weight loss of 25% or more, a significant contrast to the 16% of Wegovy users who met similar results[2]. The distinct pharmacological approach of Zepbound, which targets both GLP-1 and GIP hormones, positions it as a potentially more effective solution for obesity management compared to Wegovy's GLP-1 focused mechanism[1].